Malignant Tumors of Bone and Soft Tissue


For both the patient and clinician, the evaluation of an aggressive musculoskeletal lesion is an anxiety-producing process. By understanding principles of biopsy, staging, typical presentation, and treatment of malignant bone and soft-tissue lesions, the clinician can help inform the patient, expedite the workup, and refer to a specialty center expeditiously when a primary sarcoma is suspected. The prognosis for patients with bone and soft-tissue sarcomas has not changed substantially in the past 35 years and remains approximately 60% to 70% survival at 5 years following treatment. Abundant research activity has focused on improving systemic management for patients with recurrent and/or metastatic sarcoma. The ability to completely evaluate a patient with suspected metastatic disease of unknown primary source and assess fracture risk are two skill sets that most orthopaedic surgeons should have in their armamentarium.

This content is only available to members of the AAOS.

Please log in using the link at the top right corner of this page to access your exclusive AAOS member content.

Not a member? Become a member!